{
    "id": 30286,
    "fullName": "KIAA1217 - RET",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KIAA1217-RET results from the fusion of KIAA1217 and RET, which leads to activation of Ret downstream signaling, increased cell proliferation, induction of cell transformation in culture and tumor growth in animal models (PMID: 27150058). KIAA1217-RET has been identified in lung adenocarcinoma (PMID: 27150058).",
            "references": [
                {
                    "id": 15222,
                    "pubMedId": 27150058,
                    "title": "Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27150058"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 56243,
        "geneSymbol": "KIAA1217",
        "terms": [
            "KIAA1217",
            "ETL4",
            "SKT"
        ]
    },
    "variant": "KIAA1217 - RET",
    "createDate": "06/10/2019",
    "updateDate": "06/10/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5979,
                "geneSymbol": "RET",
                "terms": [
                    "RET",
                    "CDHF12",
                    "CDHR16",
                    "HSCR1",
                    "MEN2A",
                    "MEN2B",
                    "MTC1",
                    "PTC",
                    "RET-ELE1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 17268,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) did not inhibit proliferation of transformed lung epithelial cells expressing KIAA1217-RET in culture (PMID: 27150058).",
            "molecularProfile": {
                "id": 32440,
                "profileName": "KIAA1217 - RET"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15222,
                    "pubMedId": 27150058,
                    "title": "Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27150058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17267,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed lung epithelial cells expressing KIAA1217-RET in culture (PMID: 27150058).",
            "molecularProfile": {
                "id": 32440,
                "profileName": "KIAA1217 - RET"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15222,
                    "pubMedId": 27150058,
                    "title": "Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27150058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17266,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Caprelsa (vandetanib) inhibited Erk signaling, resulted in reduced proliferation and invasion of transformed lung epithelial cells expressing KIAA1217-RET in culture (PMID: 27150058).",
            "molecularProfile": {
                "id": 32440,
                "profileName": "KIAA1217 - RET"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15222,
                    "pubMedId": 27150058,
                    "title": "Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27150058"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32440,
            "profileName": "KIAA1217 - RET",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}